Johnson & Johnson makes 4 deals, awaits new product approvals amid slumping salesOctober 9th, 2009 J&J wheels and deals, awaits new product approvalsNEW BRUNSWICK, N.J. — Johnson & Johnson, the world's biggest healthcare company and a Dow Jones industrial average component, reports earnings for the third quarter Tuesday morning.
Shares of Acorda Therapeutics dive after FDA questions experimental multiple sclerosis drugOctober 9th, 2009 Acorda shares plunge on negative FDA reviewWASHINGTON — Shares of Acorda Therapeutics plummeted Friday after the Food and Drug Administration issued a negative opinion that questioned the safety and effectiveness of the company's multiple sclerosis drug. A panel of FDA advisers is scheduled to meet next week to vote on Acorda's Fampridine-SR, which is designed to improve patients' ability to walk.
Kimberly-Clark to purchase health care company I-Flow in deal valued at about $276 millionOctober 9th, 2009 Kimberly-Clark to buy I-Flow in $276M dealDALLAS — Kimberly-Clark Corp. said Friday that it will add higher-margin medical devices to its health care unit by purchasing health care company I-Flow Corp.
Why coelic disease patients develop osteoporosisOctober 8th, 2009 LONDON - People suffering from coelic disease, a digestive condition, are at an increased risk of developing osteoporosis, as their immune system attacks bone tissue, say researchers. It was previously believed that osteoporosis, a known complication of coeliac disease, develops in coeliac patients because they cannot properly absorb calcium and vitamin D from their diet.
Genes linked to brittle bone identifiedOctober 7th, 2009 MELBOURNE - Scientists from University of Western Australia claim to have identified new genes tied to loss of bone mineral density and osteoporosis. According to molecular geneticist and study author Associate Professor Scott Wilson of the University of Western Australia, low bone mineral density is the strongest predictor of osteoporotic fracture.
Depomed says its post-shingles pain drug succeeded it trial, and shares hit three-year highOctober 5th, 2009 Depomed says shingles pain drug meets study goalMENLO PARK, Calif. — Depomed Inc.
QLT says it sold US business, which treats prostate cancer symptoms, to Tolmar HoldingsOctober 1st, 2009 QLT sells US business to Tolmar for up to $230MNEW YORK — Biotechnology company QLT Inc. said Thursday it sold its U.S.
Drug-eluting stents safer than bare-metal ones for heart patientsSeptember 26th, 2009 WASHINGTON - A new study has shown that the use of a drug-eluting stent (paclitaxel) is safer and more effective than a bare-metal stent in heart attack patients. It also showed that administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.
Syneron Medical rises as analyst expects recovery for laser cosmetic market and raises ratingSeptember 18th, 2009 Syneron advances following upgrade to 'Outperform'NEW YORK — Shares of Syneron Medical Ltd. rose Friday after an Oppenheimer analyst upgraded the stock, saying he believes the market for laser cosmetic surgery procedures has hit a low point and will start to recover.
Lilly to cut thousands of jobs over 2 years and form 5 business units, lowering costs by $1BSeptember 14th, 2009 Lilly will reorganize and cut jobs to pare costsNEW YORK — Drugmaker Eli Lilly & Co. says it will eliminate thousands of jobs and reorganize into five business units in an effort to slash costs and speed up development of potential new drugs.
Apple CEO Steve Jobs emcees product launch for first time since receiving liver transplantSeptember 9th, 2009 Apple CEO Jobs on stage, discusses transplantSAN FRANCISCO — Apple Inc. CEO Steve Jobs returned Wednesday to the showman role that has helped define his company leadership, taking the stage for the first time since his medical leave to announce such new products as an iPod Nano that records video.
General Electric, Kraft, Atheros, Harley-Davidson, Hecla Mining are among big market moversSeptember 8th, 2009 GE, Kraft, Atheros, Harley-Davidson big moversNEW YORK — The following stocks were among those that moved substantially or traded heavily Tuesday on the New York Stock Exchange and Nasdaq Stock Market:
NYSE:
General Electric Co., up 63 cents at $14.50
J.P. Morgan analysts upgraded the industrial conglomerate to "overweight" despite worries over loss provisions at its financing unit.
Analyst says MAP Pharma will rise when more details on migraine drug are reported next weekSeptember 2nd, 2009 Analyst says new Levadex data could lift MAP stockNEW YORK — MAP Pharmaceuticals Inc. plans to share additional data from testing of its migraine drug candidate Levadex next week, and a Wedbush Morgan analyst said the results could boost MAP's share price.
Acadia Pharmaceuticals shares plunge as Parkinson's disease drug fails late-stage studySeptember 1st, 2009 Acadia shares fall on failed Parkinson's studyNEW YORK — Shares of Acadia Pharmaceuticals Inc. plunged Tuesday after the company said its drug candidate pimavanserin failed to meet key treatment goals in a late-stage study focusing on patients with Parkinson's disease psychosis.
Gene behind gum disease, osteoporosis, arthritis identifiedAugust 31st, 2009 WASHINGTON - An international team of researchers have identified a gene that is common in the development of gum disease, rheumatoid arthritis, and osteoporosis. Experts at Hospital for Special Surgery say that their findings about the gene, called interferon regulator factor-8 (IRF-8), may lead to new treatments in future.
